Risk of COVID-19 for patients with cancer

被引：306

作者：

Xia, Yang ^{[1
]}

Jin, Rui ^{[1
]}

Zhao, Jing ^{[2
]}

Li, Wen ^{[1
]}

Shen, Huahao ^{[1
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Key Lab Resp Dis Zhejiang Prov, Sch Med,Dept Resp & Critical Care Med, Hangzhou 310052, Zhejiang, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, Hangzhou 310052, Zhejiang, Peoples R China

来源：

LANCET ONCOLOGY | 2020年 / 21卷 / 04期

关键词：

D O I：

10.1016/S1470-2045(20)30150-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E180 / E180

页数：1

共 5 条

[1]

[Anonymous], CLIN CHARACETISTICS

[2]

Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.1101/2020.02.05.20020107v3, 10.1101/2020.02.05.20020107, DOI 10.1101/2020.02.05.20020107]

[3] Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China [J].

Liang, Wenhua ;

Guan, Weijie ;

Chen, Ruchong ;

Wang, Wei ;

Li, Jianfu ;

Xu, Ke ;

Li, Caichen ;

Ai, Qing ;

Lu, Weixiang ;

Liang, Hengrui ;

Li, Shiyue ;

He, Jianxing .

LANCET ONCOLOGY, 2020, 21 (03) :335-337

[4] Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion [J].

Schreiber, Robert D. ;

Old, Lloyd J. ;

Smyth, Mark J. .

SCIENCE, 2011, 331 (6024) :1565-1570

[5]

Xu Z., 2020, Lancet Respir. Med.

← 1 →